Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening
Epilepsy is a common chronic neurological disease affecting almost 3 million people in the United States and 50 million people worldwide. Despite availability of more than two dozen FDA-approved anti-epileptic drugs (AEDs), one-third of patients fail to receive adequate seizure control. Specifically...
Main Authors: | Aliesha Griffin, Kyla R. Hamling, SoonGweon Hong, Mana Anvar, Luke P. Lee, Scott C. Baraban |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.00573/full |
Similar Items
-
Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases
by: Sabrina Buoni, et al.
Published: (2015-01-01) -
A review of fenfluramine for the treatment of Dravet syndrome patients
by: Kayla Simon, et al.
Published: (2022-01-01) -
Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish Model
by: Aliesha Griffin, et al.
Published: (2020-04-01) -
The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials
by: Nicholas Aderinto, et al.
Published: (2024-03-01) -
Fenfluramine Add-On Therapy of Dravet Syndrome
by: J Gordon Millichap
Published: (2012-08-01)